JAGSNPHARM Jagsonpal Pharmaceuticals Ltd Legal Disputes Announcement 2025 - USFDA Warning Letter JAGSONPAL PHARMACEUTICALS LTD. received a warning letter from the USFDA on February 5, 2025, due to CGMP deviations; this may impact sales amounting to INR 3.5 Cr, which is 1.46% of current fiscal year sales..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Jagsonpal Pharmaceuticals Ltd